Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX GmbH has received a grant from Hamburgische Investitions und Förderbank.

December 30, 2015

News

2cureX’s German subsidiary 2cureX GmbH has received funding (EUR 450.000) from Hamburgische Investitions und Förderbank (IFB Hamburg) to broaden the IndiTreat™ product portfolio. 2cureX’s Individual Treatment test, IndiTreat™ has been developed and is presently clinically evaluated in colorectal cancer patients. The funding from IFB will allow 2cureX in collaboration with University Medical Center Hamburg-Eppendorf (UKE) to address other types solid cancers.